Global Pharma main Pfizer is discussing with the Indian authorities an expedited approval pathway to make Pfizer-BioNTech vaccine obtainable to be used within the nation, the corporate’s Chairman and CEO Albert Bourla mentioned on Monday.
Earlier in April, Pfizer mentioned that it had supplied a not-for-profit worth for its vaccine for the federal government immunisation programme in India and it stays dedicated to persevering with engagement with the federal government to make the vaccine obtainable in India.
“Pfizer is conscious that entry to vaccines is crucial to ending this pandemic. Unfortunately, our vaccine will not be registered in India though our utility was submitted months in the past.
We are at the moment discussing with the Indian authorities an expedited approval pathway to make our Pfizer-BioNTech vaccine obtainable to be used within the nation,” Bourla mentioned in a mail despatched to Pfizer India workers that he has shared on his linked.in submit.
Pfizer has earlier mentioned that, throughout the pandemic section, it’ll provide the Pfizer-BioNTech Covid-19 mRNA vaccine solely by way of authorities contracts.
“Pfizer remains committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government’s immunisation programme in the country,” the corporate had mentioned in April in e-mail response to PTI.
The Indian authorities final month allowed emergency use approval of the imported vaccines in India which have been granted emergency approval for restricted use by United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), UK Medicines and Healthcare merchandise Regulatory Agency (UK MHRA), Pharmaceuticals and Medical Device Agency (PMDA) Japan or that are listed in WHO (emergency use itemizing).